Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
Direct-to-consumer DNA testing company 23andMe has seen its valuation plummet by 99 percent from its $6 billion peak shortly after the company went public in 2021.
What will 23andMe do with the DNA data of 15 million customers?